Exact SciencesEXAS
EXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 6,600
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
125% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 9 (+5) [Q3]
76% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 68
62% more capital invested
Capital invested by funds: $7.63B [Q2] → $12.4B (+$4.77B) [Q3]
15% more call options, than puts
Call options by funds: $194M | Put options by funds: $169M
10% more funds holding
Funds holding: 530 [Q2] → 582 (+52) [Q3]
0.75% more ownership
Funds ownership: 97.85% [Q2] → 98.6% (+0.75%) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 195
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
1%
upside
Avg. target
$73
23%
upside
High target
$90
52%
upside
14 analyst ratings
14 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target | 21%upside $72 | Buy Maintained | 13 Dec 2024 |
TD Cowen Dan Brennan 48% 1-year accuracy 14 / 29 met price target | 45%upside $86 | Buy Maintained | 26 Nov 2024 |
BTIG Mark Massaro 65% 1-year accuracy 20 / 31 met price target | 26%upside $75 | Buy Maintained | 26 Nov 2024 |
Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target | 26%upside $75 | Overweight Maintained | 11 Nov 2024 |
Citigroup Patrick Donnelly 43% 1-year accuracy 13 / 30 met price target | 26%upside $75 | Buy Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 8 articles about EXAS published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates
ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It's estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter.
Neutral
Seeking Alpha
2 weeks ago
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.
Neutral
Seeking Alpha
2 weeks ago
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.
Neutral
Business Wire
2 weeks ago
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation's #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes co.
Positive
Benzinga
3 weeks ago
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.
Neutral
Benzinga
3 weeks ago
Why Is Exact Sciences Stock Trading Higher On Monday?
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Neutral
Business Wire
3 weeks ago
Exact Sciences to Participate in December Investor Conferences
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Citi Global Healthcare Conference, Miami Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET Evercore HealthCONx Conference, Miami Fireside chat on Wednesday, December 4, 2024 at 7:30 a.m. ET The webcasts can be accessed in the.
Neutral
Business Wire
3 weeks ago
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. “Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes fo.
Neutral
Seeking Alpha
1 month ago
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.
Positive
Zacks Investment Research
1 month ago
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
Exact Sciences presents new positive evidence backing the development of an MCED test.
Charts implemented using Lightweight Charts™